Please Wait...

OC // Osteocalcin

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Osteocalcin (OC), also called bone γ-carboxyglutamic acid protein (BGP), is a 49 residues containing non-collagenous protein found in bone and dental tissues. OC is produced by osteoblasts and is a vitamin K dependent protein implicated in bone formation. Initially identified as a protein limiting bone formation, new functions such as implication in glucose metabolism, reproduction and cognition have been identified since (Ducy et al., 1996; Zoch et al., 2016). OC binds to hydroxyapatite and a fraction of the newly synthetized protein is then released in blood circulation. The binding to hydroxyapatite is impaired when OC is decarboxylated (Price et al., 1981). In addition to this source of variation in biological activities, intact OC is rapidly cleaved by proteolytic enzymes and is unstable in vitro. In serum, several proteolytic fragments of OC are present and the N-terminal-mid fragment (N-Mid) is the most abundant immunoreactive form (about 30% of total OC)(Garnero et al., 1994).

Bioclinica Lab employs an automated electro-chemiluminescence immunoassay which recognizes the N-Mid OC. The assay for UcOC measurement is a twostep assay, which comprises an affinity depletion of carboxylated OC in samples with hydroxyapatite followed by an immunoassay for the measurement of the non-bound OC.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Join Bioclinica in a live #Xtalks webinar 10/31 exploring challenges & benefits of different sourcing models to man…
bioclinica (17 minutes ago)
Bioclinica contributions toward advancement of #Alzheimer's disease research & therapies showcased in 8 different s…
bioclinica (6 hours ago)
Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical…
bioclinica (Yesterday)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (Yesterday)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (Yesterday)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology…
bioclinica (Yesterday)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner